Augustin, R., Oldenburger, A., Baader-Pagler, T., Zimmermann, T., Borghardt, J., Hecksher-Sørensen, J., . . . Haebel, P. (2025). Novel NPY2R agonist BI 1820237 provides synergistic anti-obesity efficacy when combined with the GCGR/GLP-1R dual agonist survodutide. Elsevier.
Chicago Style (17th ed.) CitationAugustin, Robert, et al. Novel NPY2R Agonist BI 1820237 Provides Synergistic Anti-obesity Efficacy When Combined with the GCGR/GLP-1R Dual Agonist Survodutide. Elsevier, 2025.
MLA (9th ed.) CitationAugustin, Robert, et al. Novel NPY2R Agonist BI 1820237 Provides Synergistic Anti-obesity Efficacy When Combined with the GCGR/GLP-1R Dual Agonist Survodutide. Elsevier, 2025.
Warning: These citations may not always be 100% accurate.